Introduction

The infection is related to the use of lipid specialized pro-resolutive mediators as antiflammatory and antimicrobial therapies for respiratory diseases, including those with chronic inflammation and/or infections.

Technical features

The invention consists of a product for the treatment of inflammation and/or infections of the respiratory tract through the use of one or more lipid compounds generated by the metabolism of the polyunsaturated fatty acid DHA and called specialized pro-resolution mediators. The specialized pro-resolution mediators belong to class D of resolvins, preferably resolvin D1, D2, D3, D4, D5 and D6. The treatment has the ability to significantly reduce the presence of inflammatory cells, neutrophils, bacteria and bacterial endotoxins. The treatment therefore protects against damage to the airways, increases the body’s endogenous defenses and reduces the excessive immune response. The invention has been developed in vivo in mice and in vitro with human cells. The doses were administered orally and parenterally, using 5 micrograms/kg in vivo and nmol/L in vitro. The effect of the administration had been monitored for two weeks. The technology was validated in the laboratory and has a TRL level 4.

Possible Applications

• Cystic fibrosis and cystic fibrosis refractory to other therapies;
• Asthma;
• Chronic bronchitis;
• Emphysema;
• Viral and bacterial penumonia.

Advantages

• Show efficacy at low doses;
• Orally active;
• No side effects observed at doses 100X higher than the therapeutic doses;
• Direct antimicrobial activity;
• No induction of antibiotic resistance;
• Active against resistant bacteria strains.